Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil

References

• Liu P, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Ther 2019;4:29.
   PubMed Web of Science ®Google Scholar
• Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Transl Neurodegener 2018;7:2.
   PubMed Web of Science ®Google Scholar
• Baker NC, Ekins S, Williams AJ, et al. A bibliometric review of drug repurposing. Drug Discov Today 2018;23:661–72.
   PubMed Web of Science ®Google Scholar
• Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015;20:1027–34.
   PubMed Web of Science ®Google Scholar
• Oprea TJ, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011;8:61–9.
   PubMedGoogle Scholar
• Tranfaglia MR, Thibodeaux C, Mason DJ, et al. Repurposing available drugs for neurodevelopmental disorders: the fragile X experience. Neuropharmacology 2019;147:74–86.
   PubMed Web of Science ®Google Scholar
• Bourque M, Morissette M, Di Paolo T. Repurposing sex steroids and related drugs as potential treatment for Parkinson’s disease. Neuropharmacology 2019;147:37–54.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhao D, Liu Z, et al. Repurposing psychiatric drugs as anti-cancer agents. Cancer Lett 2018;419:257–65.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Ting MB. Pharmacological management of behavioral symptoms associated with dementia. World J Psychiatry 2014;4:72–9.
   PubMedGoogle Scholar
• Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018 Alzheimer’s Dement. Transl Res Clin Interv 2018;4:195–214.
   PubMedGoogle Scholar
• Socias SB, González-Lizárraga F, Avila CL, et al. Exploiting the therapeutic potential of ready-to-use drugs: repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Prog Neurobiol 2018;162:17–36.
   PubMed Web of Science ®Google Scholar
• Kumar S, Chowdhury S, Kumar S. In silico repurposing of antipsychotic drugs for Alzheimer’s disease. BMC Neurosci 2017;18:16.
   PubMed Web of Science ®Google Scholar
• Saavedra JM. Beneficial effects of Angiotensin II receptor blockers in brain disorders. Pharmacol Res 2017;125:91–103.
   PubMed Web of Science ®Google Scholar
• Seroquel (Quetiapine fumarate) TABLETS, 2. pp. 1–31. Available from: https://www.rxlist.com/seroquel-drug.htm [last accessed 04 Jan 2020].
   Google Scholar
• He J, Luo H, Yan B, et al. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 2009;30:1205–16.
   PubMed Web of Science ®Google Scholar
• Gareri P, Gallelli L, Pirritano D, et al. Role of quetiapine in the treatment of Alzheimer’s disease. J Gerontol Geriatric Res 2015;4:197.
   Google Scholar
• Schneider L, Yeung L, Sweitzer P, et al. Effects of Seroquel (quetiapine) on reducing hostility and psychosis in patients with Alzheimer’s disease (Poster). Washington, DC: American Psychiatric Association; 1999.
   Google Scholar
• Sharma T. Quetiapine-efficacy in different domains. Eur Neuropsychopharmacol 2001;11:S385–S90.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Yoshida K, Sugita T, et al. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuro-Psychopharmacology Biol Psychiatry 2003;27:549–53.
   PubMed Web of Science ®Google Scholar
• Park SW, Lee SK, Kim JM, et al. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett 2006;402:25–9.
   PubMed Web of Science ®Google Scholar
• Moszczyński-Pętkowski R, Majer J, Borkowska M, et al. Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines. Eur J Med Chem 2018;155:96–116.
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Sikora J, Mateusiak Ł, et al. Metformin and its sulfenamide prodrugs inhibit human cholinesterase activity. Oxid Med Cell Longev 2017;2017:7303096.
   PubMed Web of Science ®Google Scholar
• Kuźma Ł, Wysokińska H, Sikora J, et al. Taxodione and extracts from Salvia austriaca roots as human cholinesterase inhibitors. Phytother Res 2016;30:234–42.
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Fanali S, Ferranti A, et al. HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. J Pharm Biomed Anal 2002;30:969–77.
   PubMed Web of Science ®Google Scholar
• Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517–24.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621–81.
   PubMed Web of Science ®Google Scholar
• da Silva EM, Braga RCOP, Avelino-Silva TJ, Gil Junior LA. Antipsychotics in Alzheimer’s disease: a critical analysis. Dement Neuropsychol 2011;5:38–43.
   PubMedGoogle Scholar
• Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942–52.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer’s disease treatments: a descriptive review. Alzheimers Dement 2008;4:49–60.
   PubMed Web of Science ®Google Scholar
• Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD003476.
   PubMedGoogle Scholar
• McGrath AM, Jackson GA. Survey of prescribing in residents of nursing homes in Glasgow. BMJ 1996;314:611–2.
   Google Scholar
• McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997;314:266–70.
   PubMed Web of Science ®Google Scholar
• Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ 2005;330:874.
   PubMed Web of Science ®Google Scholar
• Coffey ET, Akerman KE, Courtney MJ. Brain derived neurotrophic factor induces a rapid upregulation of synaptophysin and tau proteins via the neurotrophin receptor TrkB in rat cerebellar granule cells. Neurosci Lett 1997;227:177–80.
   PubMed Web of Science ®Google Scholar
• Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003;54:235–8.
   PubMed Web of Science ®Google Scholar
• Fleming K, Thyrum P, Yeh C, et al. Cognitive improvements in psychotic subjects treated with “Seroquel” (quetiapine fumarate): an exploratory study. J Clin Psychopharmacol 2001;21:527–9.
   PubMed Web of Science ®Google Scholar
• Lafuente S, Thiamwong L. The effects of seroquel on agitation and cognition in Alzheimer’s patients: a limited integrative literature review. OAJ Gerontol Geriatric Med 2017;1:555574.
   Google Scholar
• De Deyn PP, Eriksson H, Svensson H, Study 115 investigators. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer’s disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. Int J Geriatr Psychiatry 2012;27:296–304.
   PubMed Web of Science ®Google Scholar
• Rocca P, Marino F, Montemagni C, et al. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer’s disease: preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci 2007;61:622–9.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, et al. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol 2016;14:101–15.
   PubMed Web of Science ®Google Scholar
• Mehrpouya M, Ataei S, Nili-Ahmadabadi A. Potential drug interactions with cholinesterase inhibitors in Alzheimer patients: a guideline for neurologists. J App Pharm Sci 2017;7:223–6.
   Google Scholar
• Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 2015;148:34–46.
   PubMed Web of Science ®Google Scholar
• DeNinno MP. Future directions in phosphodiesterase drug discovery. Bioorg Med Chem Lett 2012;22:6794–800.
   PubMed Web of Science ®Google Scholar
• Rotella D. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674–82.
   PubMed Web of Science ®Google Scholar
• Knott EP, Assi M, Rao SN, et al. Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair. Int J Mol Sci 2017;18:696–734.
   Web of Science ®Google Scholar
• Shafiee-Nick R, Afshari AR, Mousavi SH, et al. A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. Biomed Pharmacother 2017;94:541–56.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhu Y, Jiang Y, et al. Design, synthesis and biological evaluation of dual Acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer’s disease. Bioorg Med Chem Lett 2017;27:4180–4.
   PubMedGoogle Scholar